MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on May 18, 2005; DOI: 10.1124/mol.105.011155


0026-895X/05/6802-487-501$20.00
Mol Pharmacol 68:487-501, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.105.011155v1
68/2/487    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rodrigues-Pinguet, N. O.
Right arrow Articles by Cohen, B. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodrigues-Pinguet, N. O.
Right arrow Articles by Cohen, B. N.

Mutations Linked to Autosomal Dominant Nocturnal Frontal Lobe Epilepsy Affect Allosteric Ca2+ Activation of the {alpha}4{beta}2 Nicotinic Acetylcholine Receptor{boxs}

Nivalda O. Rodrigues-Pinguet, Thierry J. Pinguet, Antonio Figl, Henry A. Lester, and Bruce N. Cohen

Division of Biology, California Institute of Technology, Pasadena, California (N.O.R.-P., H.A.L., B.N.C.); Luxtera, Inc., Carlsbad, California (T.J.P.); and Molecular Devices Corp., Union City, California (A.F.)

Extracellular Ca2+ robustly potentiates the acetylcholine response of {alpha}4{beta}2 nicotinic receptors. Rat orthologs of five mutations linked to autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)—{alpha}4(S252F), {alpha}4(S256L), {alpha}4(+L264), {beta}2(V262L), and {beta}2(V262M)—reduced 2 mM Ca2+ potentiation of the {alpha}4{beta}2 1 mM acetylcholine response by 55 to 74%. To determine whether altered allosteric Ca2+ activation or enhanced Ca2+ block caused this reduction, we coexpressed the rat ADNFLE mutations with an {alpha}4 N-terminal mutation, {alpha}4(E180Q), that abolished {alpha}4{beta}2 allosteric Ca2+ activation. In each case, Ca2+ inhibition of the double mutants was less than that expected from a Ca2+ blocking mechanism. In fact, the effects of Ca2+ on the ADNFLE mutations near the intracellular end of the M2 region—{alpha}4(S252F) and {alpha}4(S256L)—were consistent with a straightforward allosteric mechanism. In contrast, the effects of Ca2+ on the ADNFLE mutations near the extracellular end of the M2 region—{alpha}4(+L264){beta}2, {beta}2(V262L), and {beta}2(V262M)—were consistent with a mixed mechanism involving both altered allosteric activation and enhanced block. However, the effects of 2 mM Ca2+ on the {alpha}4{beta}2, {alpha}4(+L264){beta}2, and {alpha}4{beta}2(V262L) single-channel conductances, the effects of membrane potential on the {beta}2(V262L)-mediated reduction in Ca2+ potentiation, and the effects of eliminating the negative charges in the extracellular ring on this reduction failed to provide any direct evidence of mutant-enhanced Ca2+ block. Moreover, analyses of the {alpha}4{beta}2, {alpha}4(S256L), and {alpha}4(+L264) Ca2+ concentration-potentiation relations suggested that the ADNFLE mutations reduce Ca2+ potentiation of the {alpha}4{beta}2 acetylcholine response by altering allosteric activation rather than by enhancing block.


Received January 18, 2005; accepted May 17, 2005

Address correspondence to: Bruce N. Cohen, Division of Biology 156-29, California Institute of Technology, Pasadena, CA 91125. E-mail: bncohen{at}caltech.edu




This article has been cited by other articles:


Home page
J. Neurosci.Home page
Y. Teper, D. Whyte, E. Cahir, H. A. Lester, S. R. Grady, M. J. Marks, B. N. Cohen, C. Fonck, T. McClure-Begley, J. M. McIntosh, et al.
Nicotine-Induced Dystonic Arousal Complex in a Mouse Line Harboring a Human Autosomal-Dominant Nocturnal Frontal Lobe Epilepsy Mutation
J. Neurosci., September 19, 2007; 27(38): 10128 - 10142.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
J. Turnbull, H. Lohi, J. A. Kearney, G. A. Rouleau, A. V. Delgado-Escueta, M. H. Meisler, P. Cossette, and B. A. Minassian
Sacred disease secrets revealed: the genetics of human epilepsy
Hum. Mol. Genet., September 1, 2005; 14(17): 2491 - 2500.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics